Physician profile
Benjamin R Smolar
NPI 1104913714
$857.52
in general payments reported to CMS, 2019-2025
19 companies · $206 in 2025
The $206 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $14.68 · 2021: $170 · 2022: $73.21 · 2023: $26.22 · 2024: $131 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $336 · Education: $26.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.16 |
| Education | $26.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $150.00 | 2021 | |
| Abbvie INC. | $137.06 | 2021-2025 | |
| Emd Serono, INC. | $80.77 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $55.51 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $49.92 | 2019 | |
| Genzyme Corporation | $47.62 | 2019 | |
| Genentech, INC. | $46.80 | 2022 | |
| Vanda Pharmaceuticals INC. | $39.68 | 2025 | Ponvory |
| Acadia Pharmaceuticals INC | $38.39 | 2024-2025 | Nuplazid |
| Genentech USA, INC. | $31.52 | 2019 | |
| Neurocrine Biosciences, INC. | $29.76 | 2024 | Ingrezza |
| Horizon Therapeutics Plc | $26.22 | 2023 | Uplizna |
| Merz Pharmaceuticals, LLC | $25.49 | 2024 | Inbrija, Ampyra, Xeomin |
| Lilly USA, LLC | $24.12 | 2025 | Amyvid, Kisunla |
| Azurity Pharmaceuticals, INC. | $23.40 | 2025 | Horizant |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $19.14 | 2025 | Keveyis |
| Ucb, INC. | $18.45 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.67 | 2024 | Rexulti |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Smolar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.